31 Results for "

mGlu1

" in MedChemExpress (MCE) Product Catalog:
Products (31)

31 Results for "mGlu1" in MCE Product Catalog:

  • Isoforms Recommended:
15
15 Publications Verification
Cat. No.: HY-70059
CAS No.: 201943-63-7
Target:  

mGluR

Research Areas:  

Neurological Disease

LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC50s of 21 nM, 14 nM, 7.8 μM, 8.2 μM, 170 nM, 990 nM, 22 μM for mGlu2, mGlu3, mGlu1a, mGlu5a, mGlu8, mGlu7, and mGlu4 receptors, respectively .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-100407
CAS No.: 409345-29-5
Purity:  99.94%
Target:  

mGluR

Research Areas:  

Neurological Disease

JNJ16259685 is a selective antagonist of mGlu1 receptor, and inhibits the synaptic activation of mGlu1 in a concentration-dependent manner with IC50 of 19 nM.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-124419
CAS No.: 714971-87-6
Purity:  98.42%
Target:  

mGluR

Research Areas:  

Neurological Disease

RO0711401 is a selective and orally active positive allosteric modulator of mGlu1 receptor with an EC50 of 56 nM [1] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-103558
CAS No.: 191471-52-0
Purity:  99.84%
Target:  

mGluR

Research Areas:  

Neurological Disease

LY379268 is a potent, selective and brain-penetrant mGlu2/3R agonist with EC50 values of 2.69 nM (mGlu2) and 4.48 nM (mGlu3). LY379268 has no activity on human mGlu 1a, 4a, 5a or 7a receptors. LY379268 has antioxidant and neuroprotective effects [1] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-101845
CAS No.: 932737-65-0
Purity:  99.85%
Target:  

mGluR

Research Areas:  

Cancer

FITM is a negative allosteric modulator of mGlu1 receptor with a Ki of 2.5 nM.
loading...
    loading...
Cat. No.: HY-101335
CAS No.: 147782-19-2
Purity:  ≥99.0%
Target:  

mGluR

Research Areas:  

Neurological Disease

DCG-IV is a potent agonist of group II mGluRs with EC50s of 0.35 and 0.09 μM for mGlu2R and mGlu3R, reapectively. DCG-IV is also a competitive antagonist at group I (IC50: mGlu1R/5R=389/630 μM) and III receptors (IC50: mGlu4R/6R/7R/8R= 22.5/39.6/40.1/32 μM). DCG-IV has anticonvulsive and neuroprotective effects [1] .
loading...
    loading...
Cat. No.: HY-156331
CAS No.: 1860797-76-7
Purity:  99.40%
Target:  

mGluR

Research Areas:  

Neurological Disease

VU6004909 is a blood-brain barrier penetrated mGlu1 positive allosteric modulator (PAM), with the EC50s of 25.7 nM and 31 nM for human mGlu1 and rat mGlu1, respectively. VU6004909 reduces dorsolateral striatal dopamine (DA) release in vivo and displays antipsychotic efficacy [1] .
loading...
    loading...
Cat. No.: HY-103550
CAS No.: 869802-58-4
Purity:  ≥98.0%
Target:  

mGluR

Research Areas:  

Neurological Disease

A-841720 is a potent, non-competitive and selective mGlu1 receptor antagonist with an IC50 of 10 nM for human mGlu1 receptor. A-841720 displays 34-fold selectivity over mGlu5 (IC50 of 342 nM), and no significant activity at a range of other neurotransmitter receptors, ion channels, and transporters. A-841720 has the potential for chronic pain research [1] .
loading...
    loading...
Cat. No.: HY-100605
CAS No.: 1623101-11-0
Purity:  97.30%
Target:  

mGluR

Research Areas:  

Others

VU0483605 is a potent and brain-penetrated mGlu1 receptor positive allosteric modulator (PAM). VU0483605 shows excellent mGlu1 PAM activity at both human and rat, with EC50 values of 390 and 356 nM, respectively [1].
loading...
    loading...
Cat. No.: HY-103566
CAS No.: 338736-46-2
Purity:  99.81%
LY456236 is a selective, non-competitive and orally active antagonist of glutamate receptor 1 (mGlu1), which can inhibit phosphatidylinositol hydrolysis with an IC50 of 0.145 μM. LY456236 can also inhibit EGFR, with an IC50 of 0.918 μM. LY456236 blocks cell proliferation by inhibiting the MAPK pathway, reversing the anti-apoptotic effect of DHPG (HY-12598A). LY456236 can be used in epilepsy research [1] .
loading...
    loading...
Cat. No.: HY-118179
CAS No.: 1816301-67-3
Purity:  99.30%
Target:  

mGluR

Research Areas:  

Neurological Disease

VU0486321 is a compound in a class of mGlu1 positive allosteric modulators (PAMs). VU0486321 maintains acceptable mGlu1 PAM potency, DMPK profile, CNS permeability, and mGluR selectivity.
loading...
    loading...
Cat. No.: HY-101311
CAS No.: 168560-79-0
Purity:  99.89%
Synonyms: AIDA
Target:  

mGluR

Research Areas:  

Inflammation/Immunology Cancer

UPF-523 (AIDA), a rigid (carboxyphenyl) glycine derivative, is a relatively potent and selective antagonist of group I metabotropic glutamate receptors (mGlu1a) with an IC50 of 214 μM. But UPF-523 has no effect on group II (mGlu2), group III (mGlu4) receptors or ionotropic glutamate receptors. UPF-523 has the potential for the research of the acute arthritis [1] .
loading...
    loading...
Cat. No.: HY-70059A
CAS No.: 2995269-83-3
Target:  

mGluR

Research Areas:  

Neurological Disease

(Rac)-LY341495 is the isomers of LY341495 (HY-70059) can be used as control compounds in experiments. LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC50s of 21 nM, 14 nM, 7.8 μM, 8.2 μM, 170 nM, 990 nM, 22 μM for mGlu2, mGlu3, mGlu1a, mGlu5a, mGlu8, mGlu7, and mGlu4 receptors, respectively .
loading...
    loading...
Cat. No.: HY-110191
CAS No.: 1443748-47-7
Purity:  98.70%
Target:  

mGluR

Research Areas:  

Neurological Disease Cancer

VU0469650 is a potent, selective and brain-penetrant negative allosteric modulator of mGlu1 receptor, with an IC50 of 99 nM [1].
loading...
    loading...
Cat. No.: HY-120428
CAS No.: 1341167-72-3
Target:  

mGluR

Research Areas:  

Neurological Disease

VU0410425 is an mGlu1 negative allosteric modulator. VU0410425 exhibits potent inhibitory activity for rat mGlu1 with an IC50 value of 140 nM. VU0410425 can be used for the research of central nervous system disorders [1].
loading...
    loading...
Cat. No.: HY-103563
CAS No.: 518357-51-2
Target:  

mGluR

Research Areas:  

Neurological Disease

3-MATIDA is a metabolic glutamate 1 (mGlu1) receptor antagonist. 3-MATIDA alleviates neuronal death in cerebral ischemia models. 3-MATIDA can be used in the study of neuronal injury and epileptiform activity after ischemia [1].
loading...
    loading...
Cat. No.: HY-107510
CAS No.: 446257-23-4
Target:  

mGluR

Research Areas:  

Neurological Disease

YM-230888 is an orally active, selective and allosteric mGlu1 receptor antagonist with a Ki of 13 nM. YM-230888 inhibits mGlu1-mediated inositol phosphate production in rat cerebellar granule cells with an IC50 of 13 nM. YM-230888 shows antinociceptive response in Streptozotocin (HY-13753)-induced hyperalgesia models. YM-230888 significantly reduces pain parameters in complete Freund's adjuvant (HY-153808)-induced arthritic pain models [1].
loading...
    loading...
Cat. No.: HY-124406
CAS No.: 869802-44-8
Target:  

mGluR

Research Areas:  

Neurological Disease

A-794282 is a compound with analgesic activity and is a selective mGlu1 receptor antagonist that significantly reduces pain behaviors in a postoperative pain model, but motor side effects may occur at higher doses.
loading...
    loading...
Cat. No.: HY-107513
CAS No.: 232605-26-4
Target:  

mGluR

Research Areas:  

Neurological Disease Cancer

BAY 36-7620 is a potent and noncompetitive antagonist of mGlu1 Receptor (IC50=0.16 μM) with inverse agonist activity. BAY 36-7620 inhibits tumor growth and prolongs the survival of mice with tumors by inhibiting mGlu1 receptor. BAY 36-7620 suppresses AKT phosphorylation in A549 tumors. BAY 36-762 has neuroprotective effect in acute subdural hematoma rat model.BAY 36-7620 is used in non-small cell lung cancer and breast cancer research [1] .
loading...
    loading...
Cat. No.: HY-173032
Target:  

mGluR

Research Areas:  

Neurological Disease

VU6033685 is the orally active positive allosteric modulator (PAM) for mGlu1 that positively modulates human mGlu1 and human mGlu5 with EC50 of 39 nM and 3960 nM. VU6033685 also inhibits CYP1A2, CYP2C9 and CYP2D6 with IC50 of 26, 22.3 and 23.8 μM, respectively. VU6033685 reverses amphetamine-induced rats hyperlocomotion, protects rats from MK-801 (HY-15084B)-induced cognitive impairment. VU6033685 exhibits good pharmacokinetics characteristics in rats with an oral bioavailability of 42.8% [1].
loading...
    loading...